Pathophysiological and Vascular Characteristics of Solid Tumors in Relation to Drug Delivery

Drug Delivery in Oncology: From Basic Research to Cancer Therapy

Volumn 1, Issue , 2011, Pages 33-64

  Vaupel, Peter ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Acidosis; Angiogenesis; Blood flow; Convective transport; Diffusion; Drugs; Extravasation; Hypoxia; Interstitial hypertension; Interstitial transport; Interstitium; Intratumor pharmacokinetics; Microenvironment; Transport barrier; Tumors; Vasculature

Indexed keywords

EID: 84869487940     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527634057.ch2     Document Type: Chapter

References (173)

1. Brem, S., Brem, H., Folkman, J. et al. (1976) Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res., 36, 2807-2812.
2. Vaupel, P., Kallinowski, F., and Okunieff, P. (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res., 49, 6449-6465.
3. Vaupel, P.W. (1994) Blood Flow, Oxygenation, Tissue pH Distribution, and Bioenergetic Status of Tumors, Lecture, Vol. 23, Ernst Schering Research Foundation, Berlin.
4. Vaupel, P. (2004) Tumor microenvironmental physiology and its implications for radiation oncology. Semin. Radiat. Oncol., 14, 198-206.
5. Vaupel, P. (2006) Abnormal microvasculature and defective microcirculatory function in solid tumors in Vascular-targeted Therapies in Oncology (ed. D.W. Siemann), John Wiley & Sons, Ltd, Chichester, pp. 9-29.
6. Vaupel, P. (2009) Pathophysiology of solid tumors in The Impact of Tumor Biology on Cancer Treatment and Multidisciplinary Strategies (eds M. Molls, P. Vaupel, C. Nieder, and M.S. Anscher), Springer, Berlin, pp. 51-92.
7. Schneider, V., Rischke, H.C., and Drevs, J. (2009) Tumor angiogenesis in The Impact of Tumor Biology on Cancer Treatment and Multidisciplinary Strategies (eds M. Molls, P. Vaupel, C. Nieder, and M.S. Anscher), Springer, Berlin, pp. 39-50.
8. Sivridis, E., Giatromanolaki, A., and Koukourakis, M.I. (2003) The vascular network of tumours - what is it not for? J. Pathol., 201, 173-180.
9. Carmeliet, P. and Jain, R.K. (2000) Angiogenesis in cancer and other diseases. Nature, 407, 249-257.
10. Ribatti, D., Vacca, A., and Dammacco, F. (2003) New non-angiogenesis dependent pathways for tumour growth. Eur. J. Cancer, 39, 1835-1841.
11. Bergers, G. and Benjamin, L.E. (2003) Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer, 3, 401-410.
12. Hanahan, D. and Weinberg, R.A. (2000) The hallmarks of cancer. Cell, 100, 57-70.
13. Yancopoulos, G.D., Davis, S., Gale, N.W., et al. (2000) Vascular-specific growth factors and blood vessel formation. Nature, 407, 242-248.
14. Papetti, M. and Herman, I.M. (2002) Mechanisms of normal and tumor-derived angiogenesis. Am. J. Physiol, 282, C947-C970.
15. Semenza, G.L. (2000) HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Rev., 19, 59-65.
16. Pugh, C.W., and Ratcliffe, P.J. (2003) Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med., 9, 677-684.
17. Shweiki, D., Neeman, M., Itin, A., and Keshet, E. (1995) Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc. Natl. Acad. Sci. USA, 92, 768-772.
18. Kerbel, R.S. (2000) Tumor angiogenesis: past, present and the near future. Carcinogenesis, 21, 505-515.
19. Ellis, L.M., Liu, W., Ahmad, S.A., et al. (2001) Overview of angiogenesis: biologic implications for antiangiogenic therapy. Semin. Oncol., 28, 94-104.
20. Patan, S., Munn, L.L., and Jain, R.K. (1996) Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. Microvasc. Res., 51, 260-272.
21. Ruoslahti, E. (2002) Specialization of tumour vasculature. Nat. Rev. Cancer, 2, 83-90.
22. McDonald, D.M., Munn, L., and Jain, R.K. (2000) Vasculogenic mimicry: how convincing, how novel, and how significant? Am. J. Pathol., 156, 383-388.
23. Shchors, K., and Evan, G. (2007) Tumor angiogenesis: cause or consequence of cancer? Cancer Res., 67, 7059-7061.
24. Jussila, L., and Alitalo, K. (2002) Vascular growth factors and lymphangiogenesis. Physiol. Rev., 82, 673-700.
25. Padera, T.P., Kadambi, A., di Tomaso, E., et al. (2002) Lymphatic metastasis in the absence of functional intratumor lymphatics. Science, 296, 1883-1886.
26. Hirst, D.G., and Flitney, F.W. (1997) The Physiological importance and therapeutic potential of nitric oxide in the tumour-associated vasculature in Tumour Angiogenesis (eds R. Bicknell, C.E. Lewis, and N. Ferrara), Oxford University Press, Oxford, pp. 153-167.
27. Gillies, R.J., Schornack, P.A., Secomb, T.W., and Raghunand, N. (1999) Causes and effects of heterogeneous perfusion in tumors. Neoplasia, 1, 197-207.
28. Vaupel, P., and Höckel, M. (2000) Blood supply, oxygenation status and metabolic micromilieu of breast cancers: characterization and therapeutic relevance. Int. J. Oncol., 17, 869-879.
29. Vaupel, P., Thews, O., and Hoeckel, M. (2001) Treatment resistance of solid tumors: role of hypoxia and anemia. Med. Oncol., 18, 243-259.
30. Vaupel, P. (2011) Pathophysiology of human tumours in Tumour hypoxia in the clinical setting (eds. S. Osiusky, H. Friess, P. Vaupel), Akadem-periodyka, Kiew, 21-66.
31. Konerding, M.A., Fait, E., and Gaumann, A. (2001) 3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon. Br. J. Cancer, 84, 1354-1362.
32. Reinhold, H.S., and van den Berg-Blok, A.E. (1987) Circulation physiology of tumours in Rodent Tumor Models in Experimental Cancer Therapy (eds R.F. Kallman), Pergamon Press, New York, pp. 39-42.
33. Kimura, H., Braun, R.D., Ong, E.T., et al. (1996) Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res., 56, 5522-5528.
34. Baronzio, G., Freitas, I., and Kwaan, H.C. (2003) Tumor microenvironment and hemorheological abnormalities. Semin. Thromb. Hemost., 29, 489-497.
35. Vaupel, P., Kelleher, D.K., and Thews, O. (2000) Microtopology of local perfusion, oxygenation, metabolic and energetic status, and interstitial pH in malignant tumors. Techniques and characterization. Exp. Oncol., 22, 15-25.
36. Vaupel, P., Grunewald, W.A., Manz, R., and Sowa, W. (1978) Intracapillary HbO2 saturation in tumor tissue of DS-carcinosarcoma during normoxia. Adv. Exp. Med. Biol., 94, 367-375.
37. Weiss, L., Hultborn, R., and Tveit, E. (1979) Blood flow characteristics in induced rat mammary neoplasia. Microvasc. Res., 17, S119.
38. Endrich, B., Hammersen, F., Goetz, A., and Messmer, K. (1982) Microcirculatory blood flow, capillary morphology, and local oxygen pressure of the hamster amelanotic melanoma A-Mel-3. J. Natl. Cancer Inst., 68, 475-485.
39. Wheeler, R.H., Ziessman, H.A., Medvec, B.R., et al. (1986) Tumor blood flow and systemic shunting in patients receiving intraarterial chemotherapy for head and neck cancer. Cancer Res., 46, 4200-4204.
40. Vaupel, P., and Mueller-Klieser, W. (1983) Interstitieller Raum und Mikromilieu in malignen Tumoren. Prog. Appl. Microcirc., 2, 78-90.
41. Reinhold, H.S. (1971) Improved microcirculation in irradiated tumours. Eur. J. Cancer, 7, 273-280.
42. Fukumura, D., and Jain, R.K. (2007) Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J. Cell. Biochem., 101, 937-949.
43. Young, J.S., Llumsden, C.E., Stalker, A.L., (1950) The significance of the tissue pressure of normal testicular and of neoplastic (Brown-Pearce carcinoma) tissue in the rabbit. J. Pathol. Bacteriol., 62, 313-333.
44. Gutmann, R., Leunig, M., Feyh, J., et al. (1992) Interstitial hypertension in head and neck tumors in patients: correlation with tumor size. Cancer Res., 52, 1993-1995.
45. Less, J.R., Posner, M.C., Boucher, Y., et al. (1992) Interstitial hypertension in human breast and colorectal tumors. Cancer Res., 52, 6371-6374.
46. Milosevic, M., Fyles, A., Hedley, D., et al. (2001) Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res., 61, 6400-6405.
47. Milosevic, M., Fyles, A., Hedley, D., and Hill, R. (2004) The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin. Radiat. Oncol., 14, 249-258.
48. Heldin, C.-H., Rubin, K., Pietras, K., and östman, A. (2004) High interstitial fluid pressure - an obstacle in cancer therapy. Nat. Rev. Cancer, 4, 806-813.
49. Guyton, A.C., and Hall, J.E. (2006) Textbook of Medical Physiology, 11th edn, Elsevier, Philadelphia, PA.
50. Lunt, S.J., Kalliomaki, T.M.K., Brown, A., et al. (2008) Interstitial fluid pressure, vascularity and metastasis in ectopic, orthotopic and spontaneous tumours. BMC Cancer, 8, 2.
51. Vaupel, P. (2009) Physiological mechanisms of treatment resistance in The Impact of Tumor Biology on Cancer Treatment and Multidisciplinary Strategies (eds M. Molls, P. Vaupel, C. Nieder, and M.S. Anscher), Springer, Berlin, pp. 273-290.
52. Netti, P.A., Baxter, L.T., Boucher, Y., et al. (1995) Time-dependent behavior of interstitial fluid pressure in solid tumors: Implication for drug delivery. Cancer Res., 55, 5451-5458.
53. Stohrer, M., Boucher, Y., Stangassinger, M., and Jain, R.K. (2000) Oncotic pressure in solid tumors is elevated. Cancer Res., 60, 4251-4255.
54. Durand, R.E. (2001) Intermittent blood flow in solid tumours - an under-appreciated source of drug resistance. Cancer Metastasis Rev., 20, 57-61.
55. Durand, R.E., and Aquino-Parsons, C. (2001) Non-constant tumour blood flow: iplications for therapy. Acta Oncol., 40, 862-869.
56. Durand, R.E., and Aquino-Parsons, C. (2001) Clinical relevance of intermittent tumour blood flow. Acta Oncol., 40, 929-936.
57. Primeau, A.J., Rendon, A., Hedley, D., et al. (2005) The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors. Clin. Cancer Res., 11, 8782-8788.
58. Folarin, A.A., Konerding, M.A., Timonen, J., et al. (2010) Three-dimensional analysis of tumour vascular corrosion casts using stereoimaging and micro-computed tomography. Microvasc. Res., 80, 89-98.
59. Minchinton, A.L., and Tannock, I.F. (2006) Drug penetration in solid tumours. Nat. Rev. Cancer, 6, 583-592.
60. Di Paolo, A., and Bocci, G. (2007) Drug distribution in tumors: mechanisms, role in drug resistance, and methods for modification. Curr. Oncol. Rep., 9, 109-114.
61. Tannock, I.F. (1968) The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour. Br. J. Cancer, 22, 258-273.
62. Tannock, I.F. (2001) Tumor physiology and drug resistance. Cancer Metastasis Rev., 20, 123-132.
63. Hirst, D.G., and Denekamp, J. (1979) Tumour cell proliferation in relation to the vasculature. Cell Tissue Kinet., 12, 31-42.
64. Hall, E.J., and Giaccia, A.J. (2006) Radiobiology for the Radiologist, 6th edn, Lippincott Williams & Wilkins, Baltimore, MD.
65. Trédan, O., Galmarini, C.M., Patel, K., and Tannock, I.F. (2007) Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst., 99, 1441-1454.
66. Jain, R.K. (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med., 7, 987-989.
67. Jain, R.K. (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 307, 58-62.
68. Lin, M.I., and Sessa, W.C. (2004) Antiangiogenic therapy: creating a unique "window" of opportunity. Cancer Cell, 6, 529-531.
69. Kuszyk, B., Corl, F.M., Franano, F.M., et al. (2001) Tumor transport physiology: Implications for imaging and imaging-guided therapy. Am. J. Radiol., 177, 747-753.
70. Jain, R.K. (1987) Transport of molecules across tumor vasculature. Cancer Metastasis Rev., 6, 559-593.
71. Jain, R.K. (1990) Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res., 50, 814s-819s.
72. Cairns, R., Papandreou, I., and Denko, N. (2006) Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol. Cancer Res., 4, 61-70.
73. Netti, P.A, Berk, D.A., Swartz, M.A., et al. (2000) Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res., 60, 2497-2503.
74. Lee, C.G., Heijn, M., di Tomaso, E., et al. (2000) Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res., 60, 5565-5570.
75. Willett, C.G., Boucher, Y., di Tomaso, E., et al. (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med., 10, 145-147.
76. Batchelor, T.T., Sorensen, A.G., di Tomaso, E., et al. (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell, 11, 83-95.
77. Willett, C.G., Boucher, Y., di Tomaso, E., et al. (2005) Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J. Clin. Oncol., 23, 8136-8139.
78. Moulder, J.E., and Rockwell, S. (1987) Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev., 5, 313-341.
79. Durand, R.E. (1991) Keynote address: the influence of microenvironmental factors on the activity of radiation and drugs. Int.J. Radiat. Oncol. Biol. Phys., 20, 253-258.
80. Durand, R.E. (1994) The influence of microenvironmental factors during cancer therapy. In Vivo, 8, 691-702.
81. Tannock, I.F., and Hill, R.P. (eds) (1992) The Basic Science of Oncology, 2nd edn, McGraw-Hill, New York.
82. Teicher, B.A. (ed.) (1993) Drug Resistance in Oncology, Dekker, New York.
83. Teicher, B.A. (1994) Hypoxia and drug resistance. Cancer Metastasis, 13, 139-168.
84. Teicher, B.A. (1995) Physiologic mechanisms of therapeutic resistance. Hematol. Oncol. Clin. North Am., 9, 475-506.
85. Hall, E.J. (1994) Molecular biology in radiation therapy: the potential impact of recombinant technology on clinical practice. Int.J. Radiat. Oncol. Biol. Phys., 30, 1019-1028.
86. Vaupel, P. (1997) The influence of tumor blood flow and microenvironmental factors on the efficacy of radiation, drugs and localized hyperthermia. Klin. Pädiat., 209, 243-249.
87. Chaplin, D.J., Horsman, M.R., Trotter, M.J., and Siemann, D.W. (2000) Therapeutic significance of Microenvironmental factors in Blood Perfusion and Microenvironment of Human Tumors: Implications for Clinical Radiooncology (eds M. Molls and P. Vaupel), Springer, Berlin, pp. 133-143.
88. Höckel, M., and Vaupel, P. (2001) Tumor hypoxia: definitions and current clinical, biological and molecular aspects. J. Natl. Cancer Inst., 93, 266-276.
89. Erlichman, C. (1992) Pharmacology of anticancer drugs in The Basic Science of Oncology, 2nd edn (eds I.F. Tannock and R.P. Hill), McGraw-Hill, New York, pp. 317-337.
90. Chabner, B., Allegra, C.J., Curt, G.A., and Calabresi, P. (1996) Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn, McGraw-Hill, New York, pp. 1233-1287.
91. Zeller, W.J. (1995) Bleomycin in Onkologie: Grundlagen, Diagnostik, Therapie, Entwicklungen (eds W.J. Zeller and H. zur Hausen), Ecomed, Landsberg, pp. IV-3.12, 1-7.
92. Nishi, H., Nakada, T., Kyo, S., et al. (2004) Hypoxia-inducible factorIV-3. 1 mediates upregulation of telomerase (hTERT). Mol. Cell Biol., 24, 6076-6083.
93. Anderson, C.J., Hoare, S.F., Ashcroft, M., et al. (2006) Hypoxic regulation of telomerase gene expression by transcriptional and posttranscriptional mechanisms. Oncogene, 25, 61-69.
94. Rice, G.C., Hoy, C., and Schimke, R.T. (1986) Transient hypoxia enhances the frequency of dihydrofolate reductase gene amplification in Chinese hamster ovary cells. Proc. Natl. Acad. Sci. USA, 83, 5978-5982.
95. Wei, Y., and Au, J.L.-S. (2005) Role of tumour microenvironment in chemoresistance in Integration/Interaction of Oncologic Growth (ed. G.G. Meadows), Springer, Amsterdam, pp. 285-321.
96. Vera, J.C., Castillo, G.R., and Rosen, O.M. (1991) A possible role for a mammalian facilitative hexose transporter in the development of resistance to drugs. Mol. Cell Biol., 11, 3407-3418.
97. Comerford, K.M., Wallace, T.J., Karhausen, J., et al. (2002) Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res., 62, 3387-3394.
98. Cole, S.P.C., and Tannock, I.F. (2005) Drug resistance in The Basic Science of Oncology, 4th edn (eds I.F. Tannock, R.P. Hill, R.G. Bristow, and L. Harrington), McGraw-Hill, New York, pp. 376-399.
99. Koong, A.C., Chen, E.Y., and Giaccia, A.J. (1994) Hypoxia causes the activation of nuclear factor κB through the phosphorylation of IκBa on tyrosine residues. Cancer Res., 54, 1425-1430.
100. Dachs, G.U., and Tozer, G.M. (2000) Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur. J. Cancer, 36, 1649-1660.
101. Laderoute, K.R., Calaoagan, J.M., Gustafson-Brown, C., et al. (2002) The response of c-Jun/AP-1 to chronic hypoxia is hypoxia-inducible factor 1a dependent. Mol. Cell Biol., 22, 2515-2523.
102. Laderoute, K.R., Grant, T.D., Murphy, B.J., and Sutherland, R.M. (1992) Enhanced epidermal growth factor receptor synthesis in human squamous carcinoma cells exposed to low levels of oxygen. Int. J. Cancer, 52, 428-432.
103. Ausserer, W.A., Bourrat-Floeck, B., Green, C.J., et al. (1994) Regulation of c-jun expression during hypoxic and low-glucose stress. Mol. Cell Biol., 14, 5032-5042.
104. Graeber, T.G., Peterson, J.F., Tsai, M., et al. (1994) Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol. Cell Biol., 14, 6264-6277.
105. Sanna, K., and Rofstad, E.K. (1994) Hypoxia-induced resistance to doxorubicin and methotrexate in human melanoma cell lines in vitro. Int. J. Cancer, 58, 258-262.
106. Giaccia, A.J. (1996) Hypoxic stress proteins: survival of the fittest. Semin. Radiat. Oncol., 6, 46-58.
107. Mattern, J., Kallinowski, F., Herfarth, C., and Volm, M. (1996) Association of resistance-related protein expression with poor vascularization and low levels of oxygen in human rectal cancer. Int. J. Cancer, 67, 20-23.
108. Raleigh, J.A. (1996) Hypoxia and its clinical significance. Semin. Radiat. Oncol., 6, 1-70.
109. Brown, J.M., and Giaccia, A.J. (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res., 58, 1408-1416.
110. Sutherland, R.M. (1998) Tumor hypoxia and gene expression. Implications for malignant progression and therapy. Acta Olicol., 37, 567-574.
111. Semenza, G.L. (2000) Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit. Rev. Biochem. Mol. Biol., 35, 71-103.
112. Semenza, G.L. (2000) HIF-1: mediator of physiological and pathophysiological response to hypoxia. J. Appl. Physiol., 88, 1474-1480.
113. Yokoi, K., and Fidler, I.J. (2004) Hypoxia, increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin. Cancer Res., 10, 2299-2306.
114. Vaupel, P. (2008) Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist, 13 (Suppl. 3), 21-36.
115. Vaupel, P. (2004) The role of hypoxia-induced factors in tumor progression. Oncologist, 9, 10-17.
116. Vaupel, P., Mayer, A., and Höckel, M. (2004) Tumor hypoxia and malignant progression. Methods Enzymol., 381, 335-354.
117. Höckel, M., Schlenger, K., Aral, B., et al. (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res., 56, 4509-4515.
118. Höckel, M., Schlenger, K., Höckel, S., et al. (1998) Tumor hypoxia in pelvic recurrences of cervical cancer. Int. J. Cancer, 79, 365-369.
119. Young, S.D., Marshall, R.S., and Hill, R.P. (1988) Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumour cells. Proc. Natl. Acad. Sci. USA, 85, 9533-9537.
120. Stoler, D.L., Anderson, G.R., Russo, C.A., et al. (1992) Anoxia-inducible endonuclease activity as a potential basis of the genomic instability of cancer cells. Cancer Res., 52, 4372-4378.
121. Cheng, K.C., and Loeb, L.A. (1993) Genomic instability and tumor progression: mechanistic considerations. Adv. Cancer Res., 60, 121-156.
122. Stackpole, C.W., Groszek, L., and Kalbag, S.S. (1994) Benign-to-malignant B16 melanoma progression induced in two stages in vitro by exposure to hypoxia. J. Natl. Cancer Inst., 86, 361-367.
123. Russo, C.A., Weber, T.K., Volpe, C.M., et al. (1995) An anoxia inducible endonuclease and enhanced DNA breakage as contributors to genomic instability in cancer. Cancer Res., 55, 1122-1128.
124. Graeber, T.G., Osmanian, C., Jacks, T., et al. (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature, 379, 88-91.
125. Reynolds, T.Y., Rockwell, S., and Glazer, P.M. (1996) Genetic instability induced by the tumor microenvironment. Cancer Res., 56, 5754-5757.
126. Kim, C.Y., Tsai, M.H., Osmanian, C., et al. (1997) Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions. Cancer Res., 57, 4200-4204.
127. Höckel, M., Schlenger, K., Höckel, S., and Vaupel, P. (1999) Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res., 59, 4525-4528.
128. Teicher, B.A., Lazo, J.S., and Sartorelli, A.C. (1981) Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res., 41, 73-81.
129. Teicher, B.A., Holden, S.A., Al-Achi, A., and Herman, T.S. (1990) Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaII murine fibrosarcoma. Cancer Res., 50, 3339-3344.
130. Teicher, B.A., Herman, T.S., Holden, S.A., et al. (1990) Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science, 247, 1457-1461.
131. Wóuters, A., Páuwels, B., Lardon, F. Vermorken, J.B. (2007) Implications of in vitro research on the effect of radiotherapy and chemotherapy under hypoxic conditions. Oncologist, 12, 690-712.
132. Sakata, K., Kwok, T.T., Murphy, B.J., et al. (1991) Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance. Br. J. Cancer, 64, 809-814.
133. Hickman, J.A., Potten, C.S., Merritt, A.J., and Fisher, T.C. (1994) Apoptosis and cancer chemotherapy. Philos. Trans. R. Soc. Lond. B, 345, 319-325.
134. Shannon, A.M., Bouchier-Hayes, D.J., Condron, C.M., and Toomey, D. (2003) Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat. Rev., 29, 297-307.
135. Cosse, J.-P., Ronvaux, M., and Ninane, N., et al. (2009) Hypoxia-induced decrease in p53 protein level and increase in c-jun DNA binding activity results in cancer cell resistance to etoposide. Neoplasia, 11, 976-986.
136. Harrison, L., and Blackwell, K. (2004) Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?. Oncologist, 9, 31-40.
137. Ludwig, H. (2004) rHuEPO and treatment outcomes: the preclinical experience. Oncologist, 9, 48-54.
138. Váupel, P., Höckel, M. (2008) Túmor hypoxia and therape útic resistance in Recombinant Húman Erythropoietin (rhEPO) in Clinical Oncology, 2nd edn (ed. M.R. Nowróusian), Springer, New York, pp. 283-306.
139. Van Belle, S.J.P., and Cocquyt, V. (2003) Impact of hemoglobin levels on the outcome of cancers treated with chemotherapy. Crit. Rev. Oncol. Hematol., 47, 1-11.
140. Nowrousian, M.R. (2008) Significance of anemia in cancer chemotherapy in Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology, 2nd edn (ed. M.R. Nowrousian), Springer, New York, pp. 207-248.
141. Highley, M.S., Schrijvers, D., van Oosterom, A.T., et al. (1997) Activated oxazaphosphorines are transported predominantly by erythrocytes. Ann. Oncol., 8, 1139-1144.
142. Ramanathan-Girish, S., and Boroujerdi, M. (2001) Contradistinction between doxorubicin and epirubicin: in vitro interaction with blood components. J. Pharm. Pharmacol., 53, 815-821.
143. Schrijvers, D. (2003) Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Clin. Pharmacokinet., 42, 779-791.
144. TM during weekly therapy. Cancer Chemother. Pharmacol., 57, 826-834.
145. Halonen, P., Mattila, J., Mäkipernaa, A., et al. (2006) Erythrocyte concentrations of metabolites or cumulative doses of 6-mercaptopurine and methotrexate do not predict liver changes in children treated for acute lymphoblastic leukemia. Pediatr. Blood Cancer, 46, 762-766.
146. Luo, F.R., Wyrick, S.D., and Chaney, S.G. (1999) Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus injection in rats. Cancer Chemother. Pharmacol., 44, 19-28.
147. Wildiers, H., Guetens, G., de Boeck, G., et al. (2002) Melphalan availability in hypoxia-inducible factor-1alpha+/+ and factor-1alpha-/- tumors is independent of tumor vessel density and correlates with melphalan erythrocyte transport. Int. J. Cancer, 99, 514-519.
148. Matthews, J.B., Adomat, H., and Skov, K.A. (1993) The effect of hypoxia on cytotoxicity, accumulation and DNA binding of cisplatin in Chinese hamster ovary cells. Anti-Cancer Drugs, 4, 463-470.
149. Kohnoe, S., Emi, Y., Takahashi, I., et al. (1991) Hypoxia and acidity increase the cytotoxicity of mitomycin C and carboquone to human tumor cells in vitro. AntiCancer Res., 11, 1401-1404.
150. Skarsgard, L.D., Chaplin, D.J., Wilson, D.J., et al. (1992) The effect of hypoxia and low pH on the cytotoxicity of chlorambucil. Int. J. Radiat. Oncol. Biol. Physiol., 22, 737-741.
151. Thews, O., Gassner, B., Kelleher, D.K., et al. (2007) Impact of hypoxic and acidic extracellular conditions on cytotoxicity of chemotherapeutic drugs. Adv. Exp. Med. Biol., 599, 155-161.
152. Gillies, R.J., Martinez-Zaguilán, R., Peterson, E.P., and Perona, R. (1992) Role of intracellular pH in mammalian cell proliferation. Cell. Physiol. Biochem., 2, 159-179.
153. Griffiths, J.R. (1991) Are cancer cells acidic? Br. J. Cancer, 64, 425-427.
154. Fais, S., De Milito, A., You, H., and Qin, W. (2007) Targeting vacuolar H+-ATPase as a new strategy against cancer. Cancer Res., 67, 10627-10630.
155. Wike-Hooley, J.L., Haveman, J., and Reinhold, H.S. (1984) The relevance of tumour pH to the treatment of malignant disease. Radiother. Oncol., 2, 343-366.
156. Tannock, I.F., and Rotin, D. (1989) Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res., 49, 4373-4384.
157. Song, C.W., Lyons, J.C., and Luo, Y. (1993) Intra- and extracellular pH in solid tumors: Influence on therapeutic response in Drug Resistance in Oncology (ed. B.A. Teicher), Dekker, New York, pp. 25-51.
158. Song, C.W., Park, H., and Ross, B.D. (1999) Intra- and extracellular pH in solid tumors in Antiangiogenic Agents in Cancer Therapy (ed. B.A. Teicher), Humana Press, Totowa, NJ, pp. 51-64.
159. Gerweck, L.E. (1998) Tumor pH: implications for treatment and novel drug design. Semin. Radiat. Oncol., 8, 176-182.
160. Stubbs, M. (1998) Tumour pH in Blood Perfusion and Microenvironment of Human Tumors: Implications for Clinical Radiooncology (eds M. Molls and P. Vaupel), Springer, Berlin, pp. 113-120.
161. Stubbs, M., McSheehy, P.M.J., Griffiths, J.R., and Bashford, C.L. (2000) Causes and consequences of tumour acidity and implications for treatment. Mol. Med. Today, 6, 15-19.
162. Evelhoch, J.L. (2001) pH and theraphy of human cancer in The Tumour Microenvironment: Causes and Consequences of Hypoxia and Acidity, Novartis Foundation Symposium, Vol. 240 (eds J.A. Goode and D.J. Chadwick), John Wiley & Sons, Ltd, Chichester, pp. 68-84.
163. Roepe, P.D. (2001) pH and multidrug resistance in The Tumour Microenvironment: Causes and Consequences of Hypoxia and Acidity, Novartis Foundation Symposium, Vol. 240 (eds J.A. Goode and D.J. Chadwick), John Wiley & Sons, Ltd, Chichester, pp. 232-250.
164. Raghunand, N., and Gillies, R.J. (2000) pH and drug resistance in tumours. Drug Resist. Updat., 3, 39-47.
165. Raghunand, N., and Gillies, R.J. (2001) pH and chemotherapy in The Tumour Microenvironment: Causes and Consequences of Hypoxia and Acidity, Novartis Foundation Symposium, Vol. 240 (eds J.A. Goode and D.J. Chadwick), John Wiley & Sons, Ltd, Chichester, pp. 199-211.
166. Gerweck, L.E., and Seetharaman, K. (1996) Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res., 56, 1194-1198.
167. Gerweck, L.E., Vijayappa, S., and Kozin, S. (2006) Tumor pH controls the in-vivo efficacy of weak acid and base chemotherapies. Mol. Cancer Ther., 5, 1275-1279.
168. Wei, L.Y., and Roepe, P.D. (1994) Low external pH and osmotic shock increase the expression of human MDR protein. Biochemistry, 33, 7229-7238.
169. Robinson, L.J., Roberts, W.K., Ling, T.T., et al. (1997) Human MDR1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts. Biochemistry, 36, 11169-11178.
170. Sarkaria, J.N., Kitange, G.J., James, D., et al. (2008) Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin. Cancer Res., 14, 2900-2908.
171. Valeriote, F., and van Putten, L. (1975) Proliferation-dependent cytotoxicity of anticancer agents: a review. Cancer Res., 35, 2619-2630.
172. Lotz, C., Kelleher, D.K., Gassner, B., et al. (2007) Role of the tumor microenvironment in the activity and expression of the p-glycoprotein in human colon carcinoma cells. Oncol. Rep., 17, 239-244.
173. Osinsky, S., and Vaupel, P. (2009) Tumor Microphysiology (in Russian), Naukova Dumka, Kiev.